Silymarin/curcumin loaded albumin nanoparticles coated by chitosan as muco-inhalable delivery system observing anti-inflammatory and anti COVID-19 characterizations in oleic acid triggered lung injury and in vitro COVID-19 experiment.

Publisher: Elsevier Country of Publication: Netherlands NLM ID: 7909578 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0003 (Electronic) Linking ISSN: 01418130 NLM ISO Abbreviation: Int J Biol Macromol Subsets: MEDLINE

Publication: Amsterdam : Elsevier
Original Publication: Guildford, Eng., IPC Science and Technology Press.

COVID-19 Drug Treatment*; Anti-Inflammatory Agents/*pharmacology ; Antiviral Agents/*pharmacology ; Curcumin/*pharmacology ; Lung Injury/*drug therapy ; Nanoparticles/*chemistry ; Silymarin/*pharmacology; Administration, Inhalation ; Animals ; Anti-Inflammatory Agents/administration & dosage ; Antiviral Agents/administration & dosage ; C-Reactive Protein/metabolism ; Chamomile/chemistry ; Chitosan/chemistry ; Chlorocebus aethiops ; Curcumin/administration & dosage ; Drug Delivery Systems/methods ; Flavonoids/analysis ; Flavonoids/chemistry ; Interleukin-6/metabolism ; Lung Injury/blood ; Lung Injury/chemically induced ; Lung Injury/pathology ; Male ; Mice ; Silybum marianum/chemistry ; Nanoparticles/administration & dosage ; Oleic Acid/toxicity ; Silymarin/administration & dosage ; Vero Cells ; Viral Plaque Assay

Respiratory infected by COVID-19 represents a major global health problem at moment even after recovery from virus corona. Since, the lung lesions for infected patients are still sufferings from acute respiratory distress syndrome including alveolar septal edema, pneumonia, hyperplasia, and hyaline membranes Therefore, there is an urgent need to identify additional candidates having ability to overcome inflammatory process and can enhance efficacy in the treatment of COVID-19. The polypenolic extracts were integrated into moeties of bovine serum albumin (BSA) and then were coated by chitosan as a mucoadhesion polymer. The results of interleukin-6, and c-reactive protein showed significant reduction in group treated by Encap. SIL + CUR (64 ± 0.8 Pg/μL & 6 ± 0.5 μg/μL) compared to group treated by Cham. + CUR (102 ± 0.8 Pg/μL & 7 ± 0.5 μg/μL) respectively and free capsules (with no any drug inside) (148 ± 0.6 Pg/μL & 10 ± 0.6 μg/μL) respectively. Histopathology profile was improved completely. Additionally, encapsulating silymarin showed anti-viral activity in vitro COVID-19 experiment. It can be summarized that muco-inhalable delivery system (MIDS) loaded by silymarin can be used to overcome inflammation induced by oleic acid and to overcome COVID-19.
(Copyright © 2021. Published by Elsevier B.V.)

J Agric Food Chem. 2014 Dec 3;62(48):11657-65. (PMID: 25375210)
J Nanopart Res. 2013 Apr 1;15(4):1651. (PMID: 24363607)
PLoS One. 2021 Jun 17;16(6):e0253489. (PMID: 34138966)
J Adv Pharm Technol Res. 2011 Oct;2(4):236-40. (PMID: 22247890)
Chronic Dis Transl Med. 2020 Jun;6(2):98-105. (PMID: 32550040)
Mater Sci Eng C Mater Biol Appl. 2020 Nov;116:111119. (PMID: 32806233)
Molecules. 2017 Jul 18;22(7):. (PMID: 28718803)
J Surg Res. 2014 Jun 15;189(2):274-84. (PMID: 24768138)
Toxicol Pathol. 2009 Oct;37(6):799-804. (PMID: 19773593)
J Biochem Mol Toxicol. 2009 Jan-Feb;23(1):59-70. (PMID: 19202564)
Mol Biol Rep. 2014 Mar;41(3):1325-33. (PMID: 24390242)
Mediators Inflamm. 2012;2012:956509. (PMID: 23209347)
Postgrad Med J. 2020 Jul;96(1137):403-407. (PMID: 32522846)
Shock. 2015 Dec;44(6):560-8. (PMID: 26263439)
Cell Res. 2020 Mar;30(3):269-271. (PMID: 32020029)
Int J Pharm. 2019 Dec 15;572:118824. (PMID: 31715345)
World J Crit Care Med. 2019 Sep 11;8(5):59-71. (PMID: 31559145)
Austin J Vasc Med. 2015 Jun 4;2(1):. (PMID: 26973981)
Int J Biol Macromol. 2021 Jul 31;183:171-181. (PMID: 33901560)
Thorax. 2014 Sep;69(9):819-25. (PMID: 24891325)
Crit Care. 2015 Sep 15;19:337. (PMID: 26370406)
Int J Biol Macromol. 2021 Jul 1;182:1981-1993. (PMID: 34058209)
RSC Adv. 2020 Aug 25;10(52):31385-31399. (PMID: 35520671)
Eur J Haematol. 2009 Jun;82(6):413-25. (PMID: 19220414)
Lancet Infect Dis. 2020 Oct;20(10):1135-1140. (PMID: 32526193)
Asia Pac Allergy. 2014 Oct;4(4):206-11. (PMID: 25379480)
J Clin Invest. 2015 Feb;125(2):652-64. (PMID: 25574837)
Eur J Clin Nutr. 2017 Nov;71(11):1303-1311. (PMID: 28589948)
J Appl Physiol (1985). 2015 Feb 1;118(3):377-85. (PMID: 25640150)
Int J Mol Sci. 2016 Jun 09;17(6):. (PMID: 27294919)
Int J Biol Macromol. 2021 Jul 1;182:1150-1160. (PMID: 33865895)
Nat Commun. 2020 Aug 13;11(1):4059. (PMID: 32792628)
Exp Ther Med. 2021 May;21(5):485. (PMID: 33790994)
J Clin Invest. 2003 Jun;111(12):1805-12. (PMID: 12813013)
Mol Cell Pharmacol. 2009 Jan 1;1(3):138. (PMID: 20098626)
Life Sci. 2020 Jun 15;251:117627. (PMID: 32251634)
Int J Mol Sci. 2018 Mar 06;19(3):. (PMID: 29509706)
Pharmaceutics. 2020 May 02;12(5):. (PMID: 32370293)
Respir Physiol Neurobiol. 2014 Jun 1;196:43-9. (PMID: 24594105)
Lung. 2016 Dec;194(6):945-957. (PMID: 27704259)
Clin Exp Pharmacol Physiol. 2015 Sep;42(9):988-998. (PMID: 26173462)
Am J Pathol. 2016 Oct;186(10):2614-22. (PMID: 27520356)
Heart Vessels. 2019 Dec;34(12):1961-1968. (PMID: 31104078)
PeerJ. 2014 May 22;2:e393. (PMID: 24883253)
Nat Protoc. 2021 Jun;16(6):3114-3140. (PMID: 33893470)
J Mater Sci Mater Med. 2017 Aug;28(8):120. (PMID: 28685231)
Respir Res. 2014 Sep 06;15:101. (PMID: 25189285)
Am J Pathol. 1981 Jun;103(3):376-83. (PMID: 7234970)
PLoS One. 2021 Sep 22;16(9):e0257165. (PMID: 34550994)
Mediators Inflamm. 2015;2015:260465. (PMID: 26640323)
Photochem Photobiol Sci. 2012 Jun;11(6):962-6. (PMID: 22273601)
Front Physiol. 2021 Jan 20;11:588248. (PMID: 33551831)
Nanoscale. 2016 Aug 14;8(30):14341-58. (PMID: 27439116)
Clin Exp Dermatol. 2020 Oct;45(7):902-903. (PMID: 32608046)

Keywords: Assembly; Coronavirus; Mucoadhesive

0 (Anti-Inflammatory Agents)
0 (Antiviral Agents)
0 (Flavonoids)
0 (Interleukin-6)
0 (Silymarin)
0 (interleukin-6, mouse)
2UMI9U37CP (Oleic Acid)
9007-41-4 (C-Reactive Protein)
9012-76-4 (Chitosan)
IT942ZTH98 (Curcumin)

Date Created: 20211230 Date Completed: 20220128 Latest Revision: 20231213

20231215

PMC8712435

10.1016/j.ijbiomac.2021.12.073

34968533